Antibodies to a 64,000 Mr human islet cell antigen precede the clinical onset of insulin-dependent diabetes
about
Two human glutamate decarboxylases, 65-kDa GAD and 67-kDa GAD, are each encoded by a single geneAutoimmunity to two forms of glutamate decarboxylase in insulin-dependent diabetes mellitusQuantitative assay using recombinant human islet glutamic acid decarboxylase (GAD65) shows that 64K autoantibody positivity at onset predicts diabetes typeAromatic-L-amino-acid decarboxylase, a pyridoxal phosphate-dependent enzyme, is a beta-cell autoantigenA type 1 diabetes-related protein from wheat (Triticum aestivum). cDNA clone of a wheat storage globulin, Glb1, linked to islet damageCofactor-dependent conformational heterogeneity of GAD65 and its role in autoimmunity and neurotransmitter homeostasisSite-directed mutagenesis of K396R of the 65 kDa glutamic acid decarboxylase active site obliterates enzyme activity but not antibody binding.Approaches in type 1 diabetes research: A status report.Demonstration of GAD-65 as the main immunogenic isoform of glutamate decarboxylase in type 1 diabetes and determination of autoantibodies using a radioligand produced by eukaryotic expression.Prevalence of autoantibodies to the 65- and 67-kD isoforms of glutamate decarboxylase in insulin-dependent diabetes mellitusDetection of pancreatic islet 64,000 M(r) autoantigens in insulin-dependent diabetes distinct from glutamate decarboxylaseA comparison of the baseline metabolic profiles between Diabetes Prevention Trial-Type 1 and TrialNet Natural History Study participants.Glutamate decarboxylase-, insulin-, and islet cell-antibodies and HLA typing to detect diabetes in a general population-based study of Swedish children.The use of FK 506 in new-onset type I diabetes in man.Molecular properties of HLA-DQ alleles conferring susceptibility to or protection from insulin-dependent diabetes mellitus: keys to the fate of islet beta-cells.Autoantigens in thyroid and islet autoimmunity: similarities and differences.A longitudinal study of GAD65 and ICA512 autoantibodies during the progression to type 1 diabetes in Diabetes Prevention Trial-Type 1 (DPT-1) participants.Antigen-specific therapeutic approaches in Type 1 diabetesExperimental autoimmune insulitis. Induction by T lymphocytes specific for a peptide of proinsulin.Type 1 diabetes as a model for prediction and diagnosis.The application of the diabetes prevention trial-type 1 risk score for identifying a preclinical state of type 1 diabetes.Autoreactive epitopes defined by diabetes-associated human monoclonal antibodies are localized in the middle and C-terminal domains of the smaller form of glutamate decarboxylaseIdentification of immunodominant T cell epitopes of human glutamic acid decarboxylase 65 by using HLA-DR(alpha1*0101,beta1*0401) transgenic mice.Higher autoantibody levels and recognition of a linear NH2-terminal epitope in the autoantigen GAD65, distinguish stiff-man syndrome from insulin-dependent diabetes mellitus.Membrane anchoring of the autoantigen GAD65 to microvesicles in pancreatic beta-cells by palmitoylation in the NH2-terminal domainImportance of persistent cellular and humoral immune changes before diabetes develops: prospective study of identical twins.Immunobiology of stiff-person syndrome.Human monoclonal islet cell antibodies from a patient with insulin-dependent diabetes mellitus reveal glutamate decarboxylase as the target antigen.Homing of GAD65 specific autoimmunity and development of insulitis requires expression of both DQ8 and human GAD65 in transgenic mice.Glutamic acid decarboxylase autoantibodies in preclinical insulin-dependent diabetesIdentification and characterization of glima 38, a glycosylated islet cell membrane antigen, which together with GAD65 and IA2 marks the early phases of autoimmune response in type 1 diabetes.Prediction of insulin-dependent diabetes mellitus in siblings of children with diabetes. A population-based study. The Childhood Diabetes in Finland Study Group.Novel considerations on the antibody/autoantigen system in type I (insulin-dependent) diabetes mellitus.Pancreatic islet autoantibodies as predictors of type 1 diabetes in the Diabetes Prevention Trial-Type 1.IA-2, a transmembrane protein of the protein tyrosine phosphatase family, is a major autoantigen in insulin-dependent diabetes mellitus.Inducing immune tolerance: a focus on Type 1 diabetes mellitus.Prediction and prevention of Type 1 diabetes mellitus.GAD-alum immunotherapy in Type 1 diabetes mellitus.Associations of human leukocyte antigens with autoimmune diseases: challenges in identifying the mechanism.Aberrant Accumulation of the Diabetes Autoantigen GAD65 in Golgi Membranes in Conditions of ER Stress and Autoimmunity
P2860
Q24307858-D666367F-CF19-4976-8433-E6B7FF97889AQ24561424-ECEE1937-8837-4E93-A7B7-4DAF66881655Q24617932-BEB60F97-E7DF-4D33-A74A-4D4B4B59CF5AQ28115970-D17117DE-4DC8-4C1A-83E1-00AFC4BE1F61Q28212568-4EBEA549-6932-4590-9E8D-1F0F1FF96387Q30582338-5DB929FA-C40B-44C0-8A50-2600EB1F031BQ31864279-25FD7D59-A54A-40F5-93F1-1724BB08115DQ33616086-7F3FB1C7-2F2E-4FA0-AAB0-B9AAA1268532Q33899197-E0A2DA6F-BD33-4F23-BA40-06B9471AF1B9Q33902290-045C23C1-3640-431D-B8D7-2941A7730A22Q34111857-F3B56E01-46E7-408A-A09A-07568C470B94Q34200419-F5D26831-9D10-41E1-9488-A5DC2D5639A0Q34206577-8B5B0A49-54C9-4316-B44E-EE42C5DFEF14Q34346734-FE40E9CB-D0F5-41EA-A18C-8B0719078F99Q34737266-3617A86B-20ED-4BCA-B9F8-E57BD69C95EFQ35174487-83513BA7-4390-4BB6-B398-092F6F778D0DQ35408418-536C93CE-047F-4E8C-8B3E-A430EF8DF4D3Q35762883-33C75697-7DD7-49AC-90AB-A825E157EBA2Q35798318-B5704128-C252-4607-AE2C-EC334F0C6E21Q35934762-CF5D8337-5B9E-4A1D-AE11-1267A02CE215Q36047238-1FADB173-C9CE-4916-90D4-291429AE779BQ36202374-CBD7E953-6524-47E2-8A98-9E2ACFD9CBA4Q36301274-A868D6A5-E008-48DC-87DD-F5393E408ADCQ36363509-01D75091-AF0A-4BF9-813D-269172B93930Q36533216-A3D432E2-C168-4432-BFA6-48F353CAEE41Q36885049-31605E25-5698-4FBF-8571-4B22105B26ECQ37094697-CA513A73-9C94-4A37-BF72-058362A598DCQ37195764-002CE255-8C6B-47B5-8C42-D42CB9AD5659Q37248995-DF235FBB-2686-405C-B646-C4B1A59631FAQ37255494-109F7B98-F9AC-45E2-ADD2-5230196BD785Q37356382-48E8731F-0D07-4C8D-8D78-6BD168623477Q37377371-0C0476ED-CCCA-4911-956C-9B954ED95B41Q37421850-44CC0614-EF32-41E3-8F86-C24034D0A9E8Q37437161-5C678725-C308-4615-A399-2A6FCDDD4379Q37518209-B462E66B-2816-4290-92D8-1ADB1887C1BDQ37542678-4DA06C54-477F-4AFF-93C4-80F1281213ABQ37809121-D404A4D2-22DF-49B5-9F8B-15674D80C89BQ37851966-BC30D3D2-88E5-4105-A624-AD16DBB5772AQ38569872-BEAB5411-9B9E-424A-95F3-6F31691DB8BBQ38765352-2231AEC9-E08E-452F-8F09-1108C6896D4B
P2860
Antibodies to a 64,000 Mr human islet cell antigen precede the clinical onset of insulin-dependent diabetes
description
1987 nî lūn-bûn
@nan
1987 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
1987 թվականի մարտին հրատարակված գիտական հոդված
@hy
1987年の論文
@ja
1987年論文
@yue
1987年論文
@zh-hant
1987年論文
@zh-hk
1987年論文
@zh-mo
1987年論文
@zh-tw
1987年论文
@wuu
name
Antibodies to a 64,000 Mr huma ...... of insulin-dependent diabetes
@ast
Antibodies to a 64,000 Mr huma ...... of insulin-dependent diabetes
@en
Antibodies to a 64,000 Mr huma ...... of insulin-dependent diabetes
@nl
type
label
Antibodies to a 64,000 Mr huma ...... of insulin-dependent diabetes
@ast
Antibodies to a 64,000 Mr huma ...... of insulin-dependent diabetes
@en
Antibodies to a 64,000 Mr huma ...... of insulin-dependent diabetes
@nl
prefLabel
Antibodies to a 64,000 Mr huma ...... of insulin-dependent diabetes
@ast
Antibodies to a 64,000 Mr huma ...... of insulin-dependent diabetes
@en
Antibodies to a 64,000 Mr huma ...... of insulin-dependent diabetes
@nl
P2093
P2860
P356
P1476
Antibodies to a 64,000 Mr huma ...... of insulin-dependent diabetes
@en
P2093
C de Beaufort
F Lindgren
G Eisenbarth
G J Bruining
J K Kristensen
J S Soeldner
S Baekkeskov
S Srikanta
T Mandrup-Poulsen
P2860
P304
P356
10.1172/JCI112903
P407
P577
1987-03-01T00:00:00Z